Category: breast-cancer

A new treatment option for the most common subtype of breast cancer is generating excitement among oncologists because it appears to be more effective — and cause fewer side effects — than traditional chemotherapy. The medication is sacituzumab govitecan (Trodelvy), which the U.S. Food and Drug Administration (FDA) recently approved for advanced forms of a… Continue reading Trodevly for HR-positive/HER2-negative Breast Cancer: Common Questions

A breast cancer survivor and advocate, Dana Donofree founded AnaOno, a lingerie line exclusively for women who've undergone breast cancer related surgeries. Photo Courtesy of Dana Donofree You may have heard that 1 in 8 women will develop breast cancer over the course of their lifetimes. But another statistic is that 30 percent of those… Continue reading Women With Breast Cancer Walk 2019 NYFW Runway

Black women with breast cancer are more likely to die of the disease than white women, a fact that has often been linked to less access to care. But emerging research, including a paper presented this week at the San Antonio Breast Cancer Symposium, suggests that a difference in tumor biology may also play a factor. In… Continue reading Why Do Some Black Women Have More Aggressive Breast Cancer Than White Women?

While triple-negative breast cancer is rare and only accounts for about 10 to 15 percent of all breast cancers according to the American Cancer Society, it has fewer treatment options than other breast cancers and grows and spreads more rapidly than most other breast cancer types. This type of cancer lacks certain hormone receptors that contribute… Continue reading Who Is at Risk for Triple-Negative Breast Cancer?

Jana Geyer was just 33 years old when she found a lump in her right breast in February 2018. The day after she found it, she had an ultrasound, because she was told she was too young for a mammogram. The ultrasound revealed a benign cyst, and Geyer was understandably relieved. Her doctor told her… Continue reading What to Do if You Feel a Breast Lump

Triple-negative breast cancer is a subtype of breast cancer in which the cancer has tested negative for the following markers: HER2 protein Estrogen receptors Progesterone receptors Approximately 10 to 15 percent of breast cancers are triple-negative. Black women, younger women, and those with a BRCA1 gene mutation are more likely to develop this type of… Continue reading What Is Triple-Negative Breast Cancer?

Nationwide trends show that mastectomy surgeries for both the treatment and the prevention of breast cancer are on the rise. According to Brigham and Women’s Hospital, more than 100,000 U.S. women undergo some form of mastectomy each year. Since 2000, breast reconstruction surgery (a common surgical procedure done to reconstruct the breast following a mastectomy surgery)… Continue reading Sensation-Preserving Mastectomy| Everyday Health

Ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS) are what doctors refer to as stage 0 (zero) breast cancer. With DCIS and LCIS, cancerous or precancerous cells are confined to the ducts or lobules of the breast. They typically don’t cause any obvious signs or symptoms. Some cases of DCIS and LCIS… Continue reading What Does a Diagnosis of DCIS Breast Cancer Mean?

Although breast cancer is more common in white women, Black women are more likely to develop advanced-stage disease before receiving a diagnosis, according to data from the American Cancer Society (ACS). They are also more likely to be diagnosed at a younger age and have more aggressive forms of breast cancer than white women, the… Continue reading What Black Women Should Know About Metastatic Breast Cancer

Some breast cancers may have too much of a protein called HER2 (human epidermal growth factor receptor 2) sitting on the surface of their cells. If doctors find that you have high levels of this protein, your tumor will be categorized as HER2-positive. If you have very low levels of the HER2 protein, your tumor… Continue reading What Are HER2-Positive, HER2-Negative, and HER2-Low Breast Cancers?